The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Open accessAbstract
Intermittent treatment with high-dose testosterone shows therapeutic potential in patients with castration-resistant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Self-citationThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationHUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Self-citationDehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.
Linja, M. J., Savinainen, K., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., & Visakorpi, T. (2001) · PubMed · Cited by 774
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(02)80307-x · Cited by 716
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., MacVicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2442 · Cited by 617
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements
Haffner, M. C., Aryee, M. J., Toubaji, A., Esopi, D. M., Albadine, R., Gurel, B., Isaacs, W. B., Bova, G. S., Liu, W., Xu, J., et al. (2010) · Nature Genetics · doi:10.1038/ng.613 · Cited by 608
Self-citationMostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Self-citationAttard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533
Cai, C., He, H. H., Chen, S., Coleman, I., Wang, H., Fang, Z., Chen, S., Nelson, P. S., Liu, X. S., Brown, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.001 · Cited by 454
Self-citationPROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424
Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt136 · Cited by 357
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt138 · Cited by 343
Mechanisms of the androgen receptor splicing in prostate cancer cells
Liu, L. L., Xie, N., Sun, S., Plymate, S., Mostaghel, E., & Dong, X. (2014) · Oncogene · doi:10.1038/onc.2013.284 · Cited by 315
Schrader, A. J., Boegemann, M., Ohlmann, C.-H., Schnoeller, T. J., Krabbe, L.-M., Hajili, T., Jentzmik, F., Stoeckle, M., Schrader, M., Herrmann, E., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.06.042 · Cited by 284
Kokontis, J. M. (1998) · Molecular Endocrinology · doi:10.1210/me.12.7.941 · Cited by 250
Diamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1561::aid-cncr11>3.0.co;2-z · Cited by 246
Smith, M. R., Lee, H., McGovern, F., Fallon, M. A., Goode, M., Zietman, A. L., & Finkelstein, J. S. (2008) · Cancer · doi:10.1002/cncr.23440 · Cited by 207
Bianchini, D., Lorente, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C., Ferraldeschi, R., Zivi, A., Attard, G., Chowdhury, S., & de Bono, J. S. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.020 · Cited by 204
Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., Saad, F., Egerdie, B., Sieber, P. R., Tammela, T. L. J., Ke, C., Leder, B. Z., & Goessl, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8850 · Cited by 196
Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Yu, Z., Chen, S., Sowalsky, A. G., Voznesensky, O. S., Mostaghel, E. A., Nelson, P. S., Cai, C., & Balk, S. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1863 · Cited by 196
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
Umekita, Y., Hiipakka, R. A., Kokontis, J. M., & Liao, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11802 · Cited by 195
Gao, J., Arnold, J. T., & Isaacs, J. T. (2001) · PubMed · Cited by 175
Self-citationRas signaling in prostate cancer progression
Weber, M. J., & Gioeli, D. G. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10683 · Cited by 171
Litvinov, I. V., Griend, D. J. V., Antony, L., Dalrymple, S. L., Marzo, A. M. D., Drake, C. G., & Isaacs, J. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603057103 · Cited by 126
Self-citationDenmeade, S. R., & Isaacs, J. T. (2010) · The Prostate · doi:10.1002/pros.21196 · Cited by 122
Self-citationUzgare, A. R., & Isaacs, J. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0968 · Cited by 121
Self-citationIsaacs, J. T., D’Antonio, J. M., Chen, S., Antony, L., Dalrymple, S. P., Ndikuyeze, G. H., Luo, J., & Denmeade, S. R. (2012) · The Prostate · doi:10.1002/pros.22504 · Cited by 113
Self-citationHaffner, M. C., Marzo, A. M. D., Meeker, A. K., Nelson, W. G., & Yegnasubramanian, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2044 · Cited by 108
Self-citationSedelaar, J. P. M., & Isaacs, J. T. (2009) · The Prostate · doi:10.1002/pros.21028 · Cited by 107
Self-citationCastration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Morris, M. J., Huang, D., Kelly, W. K., et al. (2009) · European Urology · doi:10.1016/j.eururo.2009.03.073 · Cited by 90
Stabilizing Androgen Receptor in Mitosis Inhibits Prostate Cancer Proliferation
Griend, D. J. V., Litvinov, I. V., & Isaacs, J. T. (2007) · Cell Cycle · doi:10.4161/cc.6.6.4028 · Cited by 78
Self-citationSzmulewitz, R. Z., Mohile, S. G., Posadas, E. M., Kunnavakkam, R., Karrison, T. G., Manchen, E., & Stadler, W. M. (2009) · European Urology · doi:10.1016/j.eururo.2009.02.022 · Cited by 74
Chuu, C., Kokontis, J. M., Hiipakka, R. A., Fukuchi, J., Lin, H., Lin, C., Huo, C., Su, L., & Liao, S. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02043.x · Cited by 70
Testosterone replacement in prostate cancer survivors with hypogonadal symptoms
Leibowitz, R. L., Dorff, T. B., Tucker, S. J., Symanowski, J. T., & Vogelzang, N. J. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08980.x · Cited by 65
Brendler, H. (1950) · Archives of Surgery · doi:10.1001/archsurg.1950.01250020438003 · Cited by 64
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
D’Antonio, J. M., Griend, D. J. V., & Isaacs, J. T. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0205 · Cited by 51
Self-citationD’Antonio, J. M., Griend, D. J. V., Antony, L., Ndikuyeze, G., Dalrymple, S. L., Koochekpour, S., & Isaacs, J. T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011475 · Cited by 39
Self-citationTestosterone preparations for clinical use in males
Behre, H. M., & Nieschlag, E. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.016 · Cited by 29
Androgen receptor abnormalities in castration-recurrent prostate cancer.
Nacusi, L. P., & Tindall, D. J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.34 · Cited by 27
Testosterone: List of Contributors
Nieschlag, E., Behre, H., & Nieschlag, S. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353 · Cited by 21
Review of guidelines on diagnosis and treatment of testosterone deficiency
Swerdloff, R. S., & Wang, C. C. L. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.019 · Cited by 11
Cited by
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Kumar, A., Coleman, I., Morrissey, C., Zhang, X., True, L. D., Gulati, R., Etzioni, R., Bolouri, H., Montgomery, B., White, T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4053 · Cited by 738
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Self-citationAndrogen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Metadata
- Authors
- Schweizer, M. T., Antonarakis, E. S., Wang, H., Ajiboye, A. S., Spitz, A., Cao, H., Luo, J., Haffner, M. C., Yegnasubramanian, S., Carducci, M. A., Eisenberger, M. A., Isaacs, J. T., & Denmeade, S. R.
- Venue
- Science Translational Medicine
- Published
- 2015-01-07
- Volume
- 7
- Issue
- 269
- Pages
- 269ra2-269ra2
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2137077335
- Cited by
- 254
- References
- 60
- FWCI
- 23.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.